Display options
Cite
Page JH, Ma J, Rexrode KM, et al. Plasma dehydroepiandrosterone and risk of myocardial infarction in women. Clin Chem. 2008;54(7):1190-6doi: 10.1373/clinchem.2007.099291.
Page, J. H., Ma, J., Rexrode, K. M., Rifai, N., Manson, J. E., & Hankinson, S. E. (2008). Plasma dehydroepiandrosterone and risk of myocardial infarction in women. Clinical chemistry, 54(7), 1190-6. https://doi.org/10.1373/clinchem.2007.099291
Page, John H, et al. "Plasma dehydroepiandrosterone and risk of myocardial infarction in women." Clinical chemistry vol. 54,7 (2008): 1190-6. doi: https://doi.org/10.1373/clinchem.2007.099291
Page JH, Ma J, Rexrode KM, Rifai N, Manson JE, Hankinson SE. Plasma dehydroepiandrosterone and risk of myocardial infarction in women. Clin Chem. 2008 Jul;54(7):1190-6. doi: 10.1373/clinchem.2007.099291. Epub 2008 May 01. PMID: 18451313; PMCID: PMC3400530.
Copy Download .nbib Format: NLM
Share it on

Clin Chem. 2008 Jul;54(7):1190-6. doi: 10.1373/clinchem.2007.099291. Epub 2008 May 01.

Plasma dehydroepiandrosterone and risk of myocardial infarction in women.

Clinical chemistry

John H Page, Jing Ma, Kathryn M Rexrode, Nader Rifai, Joann E Manson, Susan E Hankinson

Affiliations

  1. Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA. [email protected]

PMID: 18451313 PMCID: PMC3400530 DOI: 10.1373/clinchem.2007.099291

Abstract

BACKGROUND: In this study we prospectively evaluated the relationships between plasma concentrations of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEA-S) and subsequent myocardial infarction in women.

METHODS: Using case-control sampling, we selected participants from the Nurses' Health Study cohort. Blood samples were collected from 1989 to 1990 when the women were 43 to 69 years old. During follow-up through June 1998, 239 women were diagnosed with myocardial infarction (fatal and nonfatal). We matched cases 1:2 by age, cigarette smoking status, fasting status, and month of blood collection and used conditional logistic regression to adjust for potential confounders, including anthropometric factors and dietary intake.

RESULTS: Baseline median (10th, 90th percentiles) concentrations of DHEA were 17.1 (4.3, 46.7) nmol/L among women who subsequently developed myocardial infarction and 16.6 (6.1, 37.9) among controls. The risk of myocardial infarction increased with plasma concentrations of DHEA and its sulfate. Women in the highest DHEA quartile had a rate ratio (RR) of 1.27 (95% CI 0.92-1.74, P for trend = 0.008) for myocardial infarction compared with those in the lowest quartile, after adjusting for covariates. The results did not vary significantly by menopausal status, postmenopausal estrogen therapy, fasting status, or age at time of blood collection. Similar relationships between concentrations of DHEA-S and risk were observed, with an RR of 1.58 (95% CI 1.13-2.21; P for trend = 0.06) for myocardial infarction in the highest vs lowest quartile.

CONCLUSIONS: We observed a modest positive relationship between plasma concentrations of DHEA and its sulfate and the risk of subsequent myocardial infarction among predominantly postmenopausal women.

References

  1. Clin Chem. 1995 May;41(5):717-23 - PubMed
  2. Front Neuroendocrinol. 2001 Jul;22(3):185-212 - PubMed
  3. Circulation. 1995 Mar 15;91(6):1757-60 - PubMed
  4. Clin Chem. 1989 Dec;35(12):2313-6 - PubMed
  5. J Am Coll Cardiol. 1990 Nov;16(6):862-70 - PubMed
  6. Endocr Rev. 2003 Jun;24(3):313-40 - PubMed
  7. J Clin Endocrinol Metab. 1992 Aug;75(2):577-83 - PubMed
  8. Clin Chem. 1974 Apr;20(4):470-5 - PubMed
  9. N Engl J Med. 2006 Oct 19;355(16):1647-59 - PubMed
  10. JAMA. 2004 Nov 10;292(18):2243-8 - PubMed
  11. JAMA. 1996 Nov 6;276(17):1365-7 - PubMed
  12. Mech Ageing Dev. 2002 Apr 30;123(8):1101-6 - PubMed
  13. Obstet Gynecol. 1985 Feb;65(2):199-205 - PubMed
  14. Circulation. 2003 Oct 7;108(14):1688-93 - PubMed
  15. Diabetologia. 2007 Oct;50(10):2076-84 - PubMed
  16. N Engl J Med. 1986 Dec 11;315(24):1519-24 - PubMed
  17. J Clin Endocrinol Metab. 1996 Jan;81(1):59-64 - PubMed
  18. Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):1032-6 - PubMed
  19. J Clin Pharmacol. 1999 Apr;39(4):327-48 - PubMed
  20. Lancet. 1994 Jun 11;343(8911):1479-81 - PubMed
  21. Cardiovasc Drug Rev. 2002 Fall;20(3):175-98 - PubMed
  22. J Clin Endocrinol Metab. 2007 Apr;92(4):1289-95 - PubMed
  23. Cancer Epidemiol Biomarkers Prev. 1995 Sep;4(6):649-54 - PubMed

Substances

MeSH terms

Publication Types

Grant support